Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online June 10, 2013.
Copyright & Usage
© PDA, Inc. 2013
Author Information
- Stephen E. Langille, Ph.D.*
- Office of Pharmaceutical Science Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave, Bldg. 51, Rm. 4158 Silver Spring, MD 20993
- ↵* Corresponding Author: Stephen E. Langille, Ph.D., Office of Pharmaceutical Science Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave, Bldg. 51, Rm. 4158 Silver Spring, MD 20993. Telephone: 301-796-1557, e-mail: Stephen.Langille{at}fda.hhs.gov
Cited By...
Jump to section
Related Articles
Cited By...
- A Proof-of-Concept Study on a Universal Standard Kit to Evaluate the Risks of Inspectors for Their Foundational Ability of Visual Inspection of Injectable Drug Products
- Identification and Root Cause Analysis of the Visible Particles Commonly Encountered in the Biopharmaceutical Industry
- Best Practices to Quantify and Identify Particulate Matter on the Interior Surfaces of Single-Use Systems
- Development and Qualification of Visible Particle Load Analysis Methods for Injectable Drug Product Primary Packaging Components
- Tornado-inspired acoustic vortex tweezer for trapping and manipulating microbubbles
- Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach
- Micro-Flow Imaging: Estimation of the Contribution of Key Factors to the Variability of Subvisible Particle Count Measurement by a Nested Statistical Analysis
- Development of Protein-Like Reference Material for Semiquantitatively Monitoring Visible Proteinaceous Particles in Biopharmaceuticals
- Achieving "Zero" Defects for Visible Particles in Injectables
- Particulate Generation Mechanisms during Bulk Filling and Mitigation via New Glass Vial
- Particulate Study on NeoProfen, a Neonatal Injectable Product